Werewolf Therapeutics (HOWL) Operating Margin (2022 - 2026)
Werewolf Therapeutics' (HOWL) quarterly Operating Margin came in at 34.09% in Q2 2026, up 100.03% quarter-over-quarter from 135653.33% in Q4 2024.
Analysis
Werewolf Therapeutics (HOWL) Operating Margin (2022 - 2026) Analysis & Trends
Werewolf Therapeutics (HOWL) has reported Operating Margin for 4 consecutive years, with 34.09% the latest figure, recorded in Q2 2026.
- On a quarterly basis, Operating Margin changed N/A year-over-year to 34.09% in Q2 2026; TTM through Jun 2026 was 148.84%, a 48655116.0% increase from a year earlier, with the FY2024 full-year figure at 3873.37%, down 367027.0% from the prior year.
- Operating Margin was 34.09% for Q2 2026 at Werewolf Therapeutics, up from 135653.33% in the prior quarter.
- Over five years, Operating Margin peaked at 34.09% in Q2 2026 and troughed at 135653.33% in Q4 2024.
- A 4-year average of 12886.77% and a median of 273.81% in 2023 frame the typical range for Operating Margin.
- Across the five-year window, Operating Margin jumped 28587 bps in 2023 and slumped 13478978 bps in 2024, its largest moves.
- Over 4 years, Operating Margin stood at 180.96% in 2022, then plunged by 377 bps to 863.56% in 2023, then slumped by 15609 bps to 135653.33% in 2024, then jumped by 100 bps to 34.09% in 2026.
- The last three Operating Margin figures came in at 34.09% (Q2 2026), 135653.33% (Q4 2024), and 1658.79% (Q2 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.69 Bn | 192.70 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 179.87 Bn | 176.70 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 81.70 Bn | 73.71 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 54.28 Bn | 49.14 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 33.02 Bn | 29.71 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.93 Bn | 30.64 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 29.27 Bn | 29.27 Bn | 1.16 Mn | -25,380.93% |
| 10 | Werewolf Therapeutics | 46.99 Mn | 46.99 Mn | - | 34.09% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 34.09% |
| Dec 31, 2024 | -135,653.33% |
| Jun 30, 2024 | -1,658.79% |
| Mar 31, 2024 | -2,312.94% |
| Dec 31, 2023 | -863.56% |
| Sep 30, 2023 | -156.88% |
| Jun 30, 2023 | -75.08% |
| Mar 31, 2023 | -273.81% |
| Dec 31, 2022 | -180.96% |
| Sep 30, 2022 | -252.29% |
| Jun 30, 2022 | -360.95% |